Apex Drugs Profile
Key Indicators
- Authorised Capital ₹ 25.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 09-12-2024
- Company Age 35 Year, 17 Days
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 135.21 Cr
as on 09-12-2024
- Revenue %
(FY 2022)
- Net Worth 101.50%
(FY 2022)
- Total Assets -91.30%
(FY 2022)
About Apex Drugs
The Corporate was formerly known as Apex Drugs And Intermediates Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 25.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company has closed loans amounting to ₹135.21 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Apex Drugs Limited India is Shankar Dige as CFO. Shankar Dige, Kajal Damania, and Gajanana Kudva serve as directors at the Company.
- CIN/LLPIN
U24230TG1989PLC010737
- Company No.
010737
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
05 Dec 1989
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Apex Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shankar Dige  | Managing Director | 15-Sep-2021 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gajanana Kudva | Director | 29-Aug-2020 | Current |
| Kajal Damania | Director | 28-Aug-2020 | Current |
Financial Performance of Apex Drugs.
Apex Drugs Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 101.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Apex Drugs?
In 2022, Apex Drugs had a promoter holding of 99.94% and a public holding of 0.06%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mvk Lifesciences Private LimitedActive 3 years 2 monthsKajal Damania and Gajanana Kudva are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Allahabad Bank Creation Date: 01 Dec 2010 | ₹16.00 Cr | Satisfied |
Bank Of India Creation Date: 12 Sep 2008 | ₹23.85 Cr | Satisfied |
Icici Bank Limited Creation Date: 23 Apr 2007 | ₹22.20 Cr | Satisfied |
How Many Employees Work at Apex Drugs?
Unlock and access historical data on people associated with Apex Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apex Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apex Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
